注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Galmed Pharmaceuticals是一家以色列的临床阶段生物制药公司。该公司的业务重点是开发治疗肝脏疾病的疗法。该公司的主要产品是Arachmol,这是一种肝脏靶向硬脂酰辅酶A去饱和酶1,用于口服治疗NASH(非酒精性脂肪性肝炎)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Vlad Ratziu | - | - | Member of Scientific Advisory Board |
Arun J. Sanyal | - | - | Member of Scientific Advisory Board |
Shmuel Nir | 59 | 2007 | Independent Director |
Amir Poshinski | 60 | 2020 | Independent Director |
David Sidransky | 61 | 2014 | Lead Independent Director |
Allen Baharaff | 56 | 2000 | Co-Founder, President, CEO & Chairman |
José María Mato de la Paz | - | - | Member of Scientific Advisory Board |
Shomron Ben-Horin | - | - | Member of Scientific Advisory Board |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Carol L. Brosgart | 72 | 2017 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核